Sustained-release nanoparticle compositions and methods using the same

Abstract

The present invention is a composition composed of a therapeutic agent encapsulated in a copolymer of an N-alkylacrylamide, a vinyl monomer, and a polyethylene glycol (PEG) conjugate and a method for using the same in the treatment or prevention of a disease or condition.

1 . A sustained-release nanoparticle composition comprising a therapeutic agent and a cross-linked copolymer of an N-alkylacrylamide, a vinyl monomer selected from the group consisting of a vinyl alcohol, a vinyl ether, a vinyl ester, or a combination of said vinyl monomers, and a polyethylene glycol (PEG) conjugate in nanoparticle form, wherein the weight per weight ratio of the N-alkylacrylamide, vinyl monomer and (PEG) conjugate is 70-90:9-20:1-10, said therapeutic agent being encapsulated in said copolymer. 
   
   
       2 . (canceled) 
   
   
       3 . A method for preventing or treating a disease or condition comprising locally administering to a patient having or at risk of having a disease or condition, an effective amount of a composition of  claim 2  thereby preventing or treating the disease or condition in the patient. 
   
   
       4 . The sustained-release nanoparticle composition of  claim 1 , wherein said therapeutic agent is selected from the group consisting of antibiotics, antirestenotics, anti-proliferative agents, anti-neoplastic agents, chemotherapeutic agents, cardiovascular agents, anti-inflammatory agents, immunosuppressive agents, anti-apoptotic and anti-tissue damage agents. 
   
   
       5 . The sustained-release nanoparticle composition of  claim 1 , wherein said therapeutic agent comprises an anti-proliferative agent. 
   
   
       6 . The sustained-release nanoparticle composition of  claim 1 , wherein said ratio is 80:15:5. 
   
   
       7 . The sustained-release nanoparticle composition of  claim 1 , wherein said nanoparticles have an average diameter in the range of 20 nm to 100 nm as measured by transmission electron microscopy. 
   
   
       8 . The sustained-release nanoparticle composition of  claim 1 , wherein said therapeutic agent is an anti-apoptotic agent. 
   
   
       9 . The sustained-release nanoparticle composition of  claim 8 , wherein said anti-apoptotic agent is selected from the group consisting of galectin-3, (−) deprenyl, rapamycin, quercetin or a monoamine oxidase inhibitor. 
   
   
       10 . The sustained-release nanoparticle composition of  claim 1 , wherein said therapeutic agent is rapamycin. 
   
   
       12 . The method of  claim 3 , wherein said anti-proliferative agent is rapamycin.